Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review

Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e285-e292. doi: 10.1016/j.clml.2021.10.014. Epub 2021 Nov 1.


With recent advances in novel chemotherapeutic agents and increasing use of autologous hematopoietic stem cell transplant, there has been a significant improvement in outcomes for patients with AL Amyloidosis. Daratumumab, with its excellent safety and efficacy profile, appears to be an ideal treatment option for patients with newly diagnosed as well as relapsed refractory AL amyloidosis. In this systematic review, we analyzed the published literature on the role of Daratumumab in pretreated relapsed and refractory AL-amyloidosis patients using PubMed, Embase, Cochrane, and clinicaltrials.gov databases. A total of 16 studies evaluated the role of Daratumumab as monotherapy (DMT) or in combination with other chemotherapeutic agents (DCT). DMT and DCT were associated with promising efficacy with hematologic and organ responses (cardiac/renal) seen in 50%-90% and 50%-80% of the patients, respectively. Daratumumab appeared to be well tolerated with no significant treatment-related adverse events as DMT or DCT.

Keywords: AL amyloidosis; Daratumumab; Pretreated; Refractory light chain; Relapsed.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / diagnosis
  • Immunoglobulin Light-chain Amyloidosis* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • daratumumab